Alaya.bio
France - VillejuifBiotechnology
Focus: Alaya.bio is a pre-revenue biotech focused on polymeric nanoparticle CAR T immunotherapy platform for oncology and cell therapy applications. The company operates as a small, specialized player in the competitive cell therapy space.
Profile data last refreshed 8h ago · AI intelligence enriched 2mo ago
Employees
1-50
Open Jobs
2+2 this month
Stable — net +2 jobs in 30d
2 added, 0 removed. Backfill posture.
Should You Work at Alaya.bio?
AI assessmentBest suited for scientists/engineers willing to bet on early-stage platform potential with execution risk; unsuitable for those seeking stability, clinical validation, or near-term commercial upside.
Why Work Here
- Cutting-edge platform technology in CAR T immunotherapy, a high-growth therapeutic area with significant commercial potential
- Opportunity to shape early-stage company culture and scientific direction with hands-on impact in a 1-50 person organization
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Alaya.bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.